Mikrobiomik is a biopharmaceutical company founded for the research, development, production and commercialization of biologic medicines based on the human microbiome.
At Mikrobiomik we are developing a new generation of biologic medicines based on the human microbiome, focused on serious diseases, currently without therapeutic alternative such as non-alcoholic steatohepatitis, acute diverticulitis or some types of metastatic cancers.
Our first biologic medicine under investigation, MBK-01, aimed at treating intestinal infection caused by Clostridioides difficile, has finalized the phase III clinical trial, and obtained optimistically results and is expected to be launched on the European market in the first half of 2025.
